Phase II Study of TAK228 in Relapsed Lymphoma

Trial Profile

Phase II Study of TAK228 in Relapsed Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Sapanisertib (Primary)
  • Indications B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Mar 2018 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
    • 05 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Mar 2017 Planned primary completion date changed from 1 Dec 2021 to 1 Mar 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top